Non-small Cell Lung Cancer
Conditions
Brief summary
Insufficient migration and activation of tumour specific effector T cells seems to be the one important reason for inadequate host anti-tumour immune response. Ionizing radiation can induce a variety of immune responses. The goal of this randomized trial is to assess if a preoperative single fraction low dose radiation is able to improve anti-tumour immune response in operable early stage lung cancer.
Interventions
RADIATIONPreoperative radiation
Lobectomy for lung cancer following preoperative radiation
Sponsors
German Cancer Research Center
Heidelberg University
University Hospital Heidelberg
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologically proven clinical stage I to IIA pulmonary adenocarcinoma * Lung tumor is felt to be curatively resectable by the treating physicians * Sufficient pulmonary function for lobectomy according to current guidelines * The patient is free of distant metastases as confirmed by contrast-enhanced chest and upper abdomen CT-scan and by contrast-enhanced CT or MRI of the brain * Age over 50years at the time of consent due to federal radiation protection law * In female patients of childbearing potential there must be a negative pregnancy test * Eastern Cooperative Oncology Group performance status of 0,1, 2 or 3 at the time of randomization * Patients who the investigator believes can and will comply with the requirements of this protocol * Written informed consent according to good clinical practise and national/regional regulations
Exclusion criteria
* The patient shows clinical signs of pneumonia * The patient receives immunosuppressive drugs (alkylating agents, antimetabolites, methotrexate, azathioprine, mercaptopurine, cytotoxic antibodies, ciclosporin, tacrolimus, sirolimus, interferon, mycophenolate, small biological agents) * The patient has been diagnosed with a potential immune mediated disease * Elevated blood leukocyte count or erythrocyte sedimentation rate * Pregnancy * The patient has received any cancer specific treatment, including radiotherapy, immunotherapy, hormonal therapy or chemotherapy * The patient is diagnosed with a concomitant malignancy and/or has a history of malignancy within the past five years or has had a malignancy that has been in complete remission for less than 5 years * The patient needs chronic long term oxygen therapy * The patient has undergone splenectomy * The patient is known to be HIV positive * The patient has an uncontrolled bleeding disorder
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Cluster of differentiation (CD)8+ T cells in resected NSCLC | 7 days | Frequencies of CD8+ T cells in resected NSCLC tumors determined by immunohistochemistry |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| T cell subtypes in resected NSCLC | 7 days | Frequencies of CD3+, CD4+, CD45RO and Foxp3+ T cells in resected NSCLC tumors determined by immunohistochemistry and flow cytometry |
Other
| Measure | Time frame | Description |
|---|---|---|
| Tumor reactive T cells | 3 months | Frequencies of tumor reactive T cells in blood and bone marrow before radiotherapy and after surgery |
Countries
Germany
Outcome results
None listed